Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The relationships between alprazolam and metabolite concentrations and CNS effects were determined in a double-blind placebo controlled four-way crossover trial in 16 normal male volunteers. Active drug treatments consisted of 4-day regimens of 4 mg alprazolam PO daily as 2 mg bid., 1 mg qid, and 0.25 mg each hour. On days 1 and 4, the kinetics, sedative and psychomotor effects were evaluated. Plasma concentrations of the 4- and alpha-hydroxy metabolites of alprazolam were less than 10% of unchanged alprazolam levels on both days. Accumulation of these metabolites and alprazolam was dependent on alprazolam half-life (11.6 h). Acute and chronic tolerance to the sedative and psychomotor effects was observed with all active drug treatments. All alprazolam treatments resulted in significantly greater sedation than placebo on days 1 and 4. However, on day 4, sedation was 16-36% less than observed on day 1, despite plasma concentrations 1.4-2.76 times the day 1 concentrations. Sedation from alprazolam was reduced in each successive study phase, suggesting a tolerance which was sustained during the 10-day washout between phases. By day 4, psychomotor performance was not different from placebo, indicating more complete development of tolerance than occurred for the sedative effect. Sedation and psychomotor impairment on day 1 were greatest with 2 mg alprazolam bid. During the initiation of therapy, the patient will likely experience less sedation and psychomotor impairment with smaller, more frequent doses. Since tolerance develops to these effects, the advantage of more frequent dosing regimen dissipates by the 4th day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tolerance to some side effects of BZDs can also develop.”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [195]
In the citing paper
“The onset of tolerance to the sedative effects of BZDs usually occurs within 1-2 weeks (194,195).”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [195]
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
Statistical Principles in Experimental Design
Myers, J. L., & Winer, B. J. (1964) · The American Journal of Psychology · doi:10.2307/1419292 · Cited by 8,058
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
Sedative-hypnotics and human performance
Johnson, L. C., & Chernik, D. A. (1982) · Psychopharmacology · doi:10.1007/bf00435262 · Cited by 206
Comparison of Alprazolam, Imipramine, and Placebo in the Treatment of Depression
Feighner, J. P. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330460039029 · Cited by 203
Sedative-hypnotics and human performance.
Johnson, L. C., & Chernik, D. A. (1981) · PsycEXTRA Dataset · doi:10.1037/e477732004-001 · Cited by 199
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Smith, R. B., Kroboth, P. D., VanderLugt, J. T., Phillips, J. P., & Juhl, R. P. (1984) · Psychopharmacology · doi:10.1007/bf00431449 · Cited by 117
Self-citationAlprazolam Kinetics in the Elderly: Relation to Antipyrine Disposition
Greenblatt, D. J. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790030057007 · Cited by 104
Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam
Ellinwood, E. H., Heatherly, D. G., Nikaido, A. M., Bjornsson, T. D., & Kilts, C. D. (1985) · Psychopharmacology · doi:10.1007/bf00427897 · Cited by 86
Research works printed but not linked: 3
- Dixon WJ, editor (1983) BMPD Statistical Software. University of California Press, Los Angeles
- Fabre LF, Mclendon DM (1980) A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res Clin Exp 27:474–482
- SAS Institute Inc (1985) SAS user's Guide: Statistics, Version 5 Edition. Cary, NC
Cited by
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Clinical Pharmacokinetics of Alprazolam: Therapeutic Implications
Greenblatt, D. J., & Wright, C. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00003 · Cited by 352
Pharmacodynamics in Older Adults: A Review
Bowie, M. W., & Slattum, P. W. (2007) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2007.10.001 · Cited by 266
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121030-00002 · Cited by 182
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00003 · Cited by 177
Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy
Obach, R. S. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005439 · Cited by 159
Pharmacokinetics of the Newer Benzodiazepines
Garzone, P. D., & Kroboth, P. D. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916060-00002 · Cited by 164
Self-citationvon Moltke, L., Greenblatt, D., Cotreau‐Bibbo, M., Harmatz, J., & Shader, R. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04317.x · Cited by 161
Verster, J. C., & Volkerts, E. R. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00003.x · Cited by 150
Fleishaker, J. C., & Hulst, L. K. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00195913 · Cited by 134
Verster, J. C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00310-x · Cited by 128
Treatment of Premenstrual Dysphoria With Alprazolam
Harrison, W. M. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150070011 · Cited by 103
Griebel, G., Blanchard, D. C., Jung, Á. H., Lee, J., Masuda, C., & Blanchard, R. J. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00121-2 · Cited by 106
Barbhaiya, R. H., Shukla, U. A., Kroboth, P. D., & Greene, D. S. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00003 · Cited by 95
Self-citationLasher, T., Fleishaker, J. C., Steenwyk, R. C., & Antal, E. J. (1991) · Psychopharmacology · doi:10.1007/bf02246031 · Cited by 96
Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment
Dorne, J. L. C. M., Walton, K., & RENWICK, A. G. (2003) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00209-0 · Cited by 95
Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines
Laurijssens, B. E., & Greenblatt, D. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630010-00004 · Cited by 92
Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment
Cowley, D. S., Roy-Byrne, P. P., Radant, A., Ritchie, J. C., Greenblatt, D. J., Nemeroff, C. B., & Hommer, D. W. (1995) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380249 · Cited by 87
Linnoila, M., Stapleon, J. M., Lister, R. G., Moss, H. B., Lane, E., Granger, A., Greenblatt, D. J., & Eckardt, M. J. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315578 · Cited by 70
Anderson, B. J., Exarchos, H., Lee, K., & Brown, T. C. K. (1990) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9001800205 · Cited by 68
Leufkens, T., Vermeeren, A., Smink, B. E., van Ruitenbeek, P., & Ramaekers, J. G. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0669-8 · Cited by 83
Alprazolam absorption kinetics affects abuse liability
Mumford, G. K., Evans, S. M., Fleishaker, J. C., & Griffiths, R. R. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90162-0 · Cited by 63
Coadministration of Nefazodone and Benzodiazepines
Greene, D. S., Salazar, D. E., Dockens, R. C., Kroboth, P. D., & Barbhaiya, R. H. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00003 · Cited by 61
Self-citationLinnoila, M., Stapleton, J. M., Lister, R. G., Moss, H. B., Lane, E., Granger, A., & Eckardt, M. J. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf02657051 · Cited by 58
Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.
Oo, C., Kuhn, R., Desai, N., Wright, C., & McNamara, P. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05778.x · Cited by 57
Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects
Kroboth, P. D., Smith, R. B., & Erb, R. J. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.32 · Cited by 57
Self-citationCubitt, H. E., Yeo, K. R., Howgate, E. M., Rostami-Hodjegan, A., & Barter, Z. E. (2011) · Xenobiotica · doi:10.3109/00498254.2011.560294 · Cited by 56
Bertz, R., Kroboth, P. D., Kroboth, F. J., Reynolds, I. J., Salek, F. S., Wright, C. E., & Smith, R. B. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36707-2 · Cited by 53
Self-citationAllen, D., Curran, H. V., & Lader, M. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265843 · Cited by 51
Orally Administered Progesterone Enhances Sensitivity to Triazolam in Postmenopausal Women
McAuley, J. W., Reynolds, I. J., Kroboth, F. J., Smith, R. B., & Kroboth, P. D. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00002 · Cited by 50
Self-citationDerry, C. L., Kroboth, P. D., Pittenger, A. L., Kroboth, F. J., Corey, S. E., & Smith, R. B. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00008 · Cited by 47
Self-citationRawden, H. C., Carlile, D. J., Tindall, A., Hallifax, D., Galetin, A., Ito, K., & Houston, J. B. (2005) · Xenobiotica · doi:10.1080/00498250500162870 · Cited by 45
Gladsjo, J. A., Rapaport, M. H., McKinney, R., Auerbach, M., Hahn, T., Rabin, A., Oliver, T., Hazen, A. L., & Judd, L. L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00003 · Cited by 44
A Fatality Due To Alprazolam Intoxication
Jenkins, A. J., LEVINE, B. S., Locke, J. L., & Smialek, J. E. (1997) · Journal of Analytical Toxicology · doi:10.1093/jat/21.3.218 · Cited by 40
Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing
Kroboth, P. D., McAuley, J. W., & Smith, R. B. (1990) · Psychopharmacology · doi:10.1007/bf02243999 · Cited by 35
“If the relationship between alprazolam effect and concentration described for young normal subjects (Smith et al. 1984; Smith and Kroboth 1987; Kroboth et al. 1988) also applies to the elderly, elderly men should experience greater effects than young men given the same doses.”
BackgroundMethodResultSelf-citationFleishaker, J. C., Phillips, J. P., Eller, M. G., & Smith, R. B. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03379.x · Cited by 35
Self-citationCoadministration of Nefazodone and Benzodiazepines: I. Pharmacodynamic Assessment
Kroboth, P. D., Folan, M. M., Lush, R. M., Chaikin, P. C., Shukla, U., Barbhaiya, R. H., & Salazar, D. E. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00002 · Cited by 34
Self-citationKunsman, G. W., Manno, J. E., Manno, B. R., Kunsman, C. M., & Przekop, M. A. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb05633.x · Cited by 33
The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment
Emilien, G. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00077-2 · Cited by 30
Influence of Drug Formulation on Drug Concentration-Effect Relationships
Castañeda‐Hernández, G., Caillé, G., & du Souich, P. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00006 · Cited by 29
Roy-Byre, P., Fleishaker, J. C., Arnett, C. D., Dubach, M. F., Stewart, J., Radant, A. D., Veith, R. C., & Graham, M. M. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.18 · Cited by 28
Clonazepam and Sertraline: Absence of Drug Interaction in a Multiple-Dose Study
Bonate, P. L., Kroboth, P. D., Smith, R. B., Suárez, E. C., & Oo, C. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00005 · Cited by 26
Self-citationMarks, K. R., Lile, J. A., Stoops, W. W., & Rush, C. R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3449-x · Cited by 25
Alprazolam in End‐Stage Renal Disease: I. Pharmacokinetics
Schmith, V. D., Piraino, B., Smith, R. B., & Kroboth, P. D. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03740.x · Cited by 24
Self-citationGas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity
Greenblatt, D. J., Javaid, J. I., Locniskar, A., Harmatz, J. S., & Shader, R. I. (1990) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)82163-5 · Cited by 24
Chowdhury, Z. S., Morshed, M. M., Shahriar, M., Bhuiyan, M. A., Islam, S. M. A., & Sayeed, M. S. B. (2016) · Behavioural Neurology · doi:10.1155/2016/3730940 · Cited by 23
Fleishaker, J. C., Garzone, P. D., Chambers, J. H., Sirocco, K. Y., & Weingartner, H. (1995) · Psychopharmacology · doi:10.1007/bf02246190 · Cited by 30
Fleishaker, J. C., & Phillips, J. P. (1989) · Psychopharmacology · doi:10.1007/bf00634449 · Cited by 21
Hossain, M. S., Wright, E., Baweja, R. K., Ludden, T. M., & Miller, R. (1997) · Pharmaceutical Research · doi:10.1023/a:1012041920119 · Cited by 21
Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.
Fleishaker, J. C., Phillips, J. P., Smith, T. C., & Smith, R. B. (1989) · Pharmaceutical Research · doi:10.1023/a:1015975214070 · Cited by 21
Self-citationAllqvist, A., Wennerholm, A., Svensson, J., & Mirghani, R. A. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.10.012 · Cited by 20
Bond, A. J., Silveira, J. C., & LADER, M. H. (1991) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470060305 · Cited by 20
Cleton, A., Mazee, D., Voskuyl, R. A., & Danhof, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702499 · Cited by 20
Miller, R. L., & DeVane, C. L. (1988) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83150-3 · Cited by 20
Pharmacokinetics and Psychomotor Performance of Alprazolam: Concentration—Effect Relationship
Wright, C. E., Sisson, T. L., Fleishaker, J. C., & Antal, E. J. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04309.x · Cited by 17
Absence of effect of food on alprazolam absorption from sustained release tablets
Eller, M. G., & Della‐Coletta, A. A. (1990) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510110104 · Cited by 17
Coadministration of Nefazodone and Benzodiazepines
Greene, D. S., Salazar, D. E., Dockens, R. C., Kroboth, P. D., & Barbhaiya, R. H. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00004 · Cited by 16
Self-citationThe pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons
Ajir, K., Smith, M. F., Lin, K., Anderson, D., Nuccio, I., Zheng, Y., Poland, R. E., Fleishaker, J. C., & Chambers, J. H. (1997) · Psychopharmacology · doi:10.1007/s002130050189 · Cited by 15
Nagasaki, T., Ohkubo, T., Sugawara, K., Yasui, N., Otani, K., & Kaneko, S. (1997) · Analytical Sciences · doi:10.2116/analsci.13.245 · Cited by 11
Pharmacokinetics of alprazolam in elderly patients with multiple diseases
Mühlberg, W., Rieck, W., Arnold, E., Ott, G., & Lungershausen, E. (1997) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(96)00774-1 · Cited by 10
Sedative-Hypnotics and Anxiolytics
Arnaout, B., & Petrakis, I. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_23 · Cited by 10
Acute Tolerance and Reversal of the Motor Control Effects of Midazolam
Coldwell, S. E., Kaufman, E., Milgrom, P., Kharasch, E. D., Chen, P., Mautz, D., & Ramsay, D. S. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00458-9 · Cited by 10
Metabolism and Distribution of 1-[14C]Alprazolam in Rats
Banks, W. R., Yamakita, H., & Digenis, G. A. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810815 · Cited by 10
Fleishaker, J. C., Hulst, L. K., Smith, T. C., & Friedman, H. L. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00266350 · Cited by 9
Influence of Endogenous Progesterone on Alprazolam Pharmacodynamics
McAuley, J. W., & Friedman, C. I. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199906000-00006 · Cited by 9
Fleishaker, J. C., Sisson, T. L., Sramek, J. J., Conrad, J. G., Verof, A. E., & Cutler, N. R. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb04689.x · Cited by 9
Tanaka, E., Nakamura, T. K., Terada, M., Shinozuka, T., & Honda, K. (2007) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2006.11.004 · Cited by 8
Clinical pharmacokinetics of alprazolam extended release: a summary
Wright, C. E. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85100-3 · Cited by 8
Fleishaker, J. C., Smith, T. C., Friedman, H. L., & Phillips, J. P. (1991) · Psychopharmacology · doi:10.1007/bf02244306 · Cited by 8
Alprazolam: just another benzodiazepine?
O’Shea, B. (1989) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700015378 · Cited by 9
Time-Dependent Sensitization to Triazolam? An Observation in Three Studies
Kroboth, P. D., McAuley, J. W., & Derry, C. L. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00007 · Cited by 7
Self-citationFleishaker, J. C., Smith, T. C., Friedman, H. L., & Hulst, L. K. (1992) · Clinical Drug Investigation · doi:10.1007/bf03258394 · Cited by 7
Hayakawa, Y., Rospo, C. C., Bartmann, A. P., King, A., Roebling, R., & Chanteux, H. (2024) · Epilepsia · doi:10.1111/epi.17901 · Cited by 6
The role of CYP3A4/5 in alprazolam metabolism
Allqvist, A. (2010) · Figshare · Cited by 3
Currie, K. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc102 · Cited by 1
The Benzodiazepines: Kinetic-Dynamic Relationships
Greenblatt, D. J. (1993) · Springer eBooks · doi:10.1007/978-1-4757-1520-0_23
Ojardias, É. (2020) · theses.fr (ABES) · doi:10.70675/816a44dbz52acz44a0z87ddz7694f3699601
Metadata
- Authors
- Smith, R. B., & Kroboth, P. D.
- Affiliations
- University of Pittsburgh (US)
- ORCID
- Smith, R. B.
- Venue
- Psychopharmacology
- Published
- 1987-09
- Volume
- 93
- Issue
- 1
- Pages
- 105-112
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1984291639
- Cited by
- 76
- References
- 20
- Citations by year
- 2024: 1 · 2016: 1 · 2014: 1 · 2013: 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- alprazolam, dosing regimen, drug tolerance, sedation, psychomotor impairment, plasma drug concentration, drug accumulation, half-life, benzodiazepines, dosing frequency
- MeSH terms
- Adult, Alprazolam, Arousal, Biotransformation, Clinical Trials as Topic, Dose-Response Relationship, Drug, Double-Blind Method, Drug Tolerance, Humans, Kinetics, Male, Metabolic Clearance Rate, Middle Aged, Psychomotor Performance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.